Navigation Links
Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
Date:10/28/2008

- Presentation to Be Webcast Live On Company's Website -

TUSTIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that senior management will present at the BIO Investor Forum 2008 on Thursday, October 30, 2008 at 3:45 pm PDT (6:45 pm EDT). The conference will be held at the Palace Hotel in San Francisco.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://investorforum.bio.org/opencms/bif/2008/

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio- manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
8. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
9. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at till det ... Science" som hålls i Wien ... undersökning med internationella forskare och vetenskapsmän som ... hälsovetenskapens två största utmaningar bristen på incitament ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... an invitation for reflection, and this one is no different. These ... and well no doubt look back on 2005 and pronounce it ... the overall scheme of things, the previous four years were a ... Sure, it stung like hell and a lot was lost on ...
... promised, our latest e-mail newsletter contains the most-read stories from our ... around 30,000 visitors a month to over 70,000 last month, many ... weve paid attention to what drew your interest. , ,Let ... for Fusion2006. The conference isnt until March 2 and were more ...
... of health care in the United States are enough to ... one in seven Americans (15.7 percent) lack health insurance. Thats ... the latest federal figures, health spending accounts for 15.3 percent ... in 2003 works out to $5,670 for each American. By ...
Cached Biology Technology:2005: the year of the comeback 22005: the year of the comeback 3Health care economics make definition of 'cost' problems difficult 2Health care economics make definition of 'cost' problems difficult 3
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... the oceans, gut microbes and STIs are just some ... be covered next week at the Society for General ... and Micro-organisms, the event takes place 29 March-1 April, ... experts deliver talks in an exciting mixture of symposia, ...
... three genes that could shed light on the genetic causes ... stroke. Researchers at the University of Edinburgh have discovered ... long it takes blood to clot. The team thinks ... could help further our understanding of conditions such as deep ...
... WI, March 22nd, 2010-Riparian areas, ecosystems caught between ... spatial and temporal variability. Effectively managing and protecting ... understanding these concepts. Fortunately, scientists are investigating new ... experiences. One of those approaches is photography. ...
Cached Biology News:Top microbiology experts meet in Edinburgh at SGM Spring Conference 2010 2Study finds genes that keep watch on blood clotting time 2Learning about riparian areas from photographs 2
...
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Biology Products: